Education
About Us
Working with TipRanks
Follow Us
Agenus (AGEN)
NASDAQ:AGEN
AGEN Stock Chart & Stats
$2.96
-$0.06(-1.69%)
At close: 4:00 PM EST
$2.96
-$0.06(-1.69%)
Day’s Range― - ―
52-Week Range$1.38 - $7.34
Previous CloseN/A
Volume199.21K
Average Volume (3M)425.46K
Market Cap
$99.30M
Enterprise Value$142.98M
Total Cash (Recent Filing)$3.46M
Total Debt (Recent Filing)$45.77M
Price to Earnings (P/E)0.5
Beta3.39
Next Earnings
Mar 16, 2026EPS Estimate
-1.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.94
Shares Outstanding34,008,350
10 Day Avg. Volume308,731
30 Day Avg. Volume425,457
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-0.18
Price to Sales (P/S)0.57
P/FCF Ratio-0.37
Enterprise Value/Market Cap1.44
Enterprise Value/Revenue1.34
Enterprise Value/Gross Profit1.66K
Enterprise Value/Ebitda4.29
Forecast
1Y Price Target
$23.00Price Target Upside677.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)1.5
Revenue Forecast (FY)$179.52M
Bulls Say, Bears Say
Bulls Say
Clinical Progress - BOT+BAL DataPublication of durable Phase 1b ovarian cohort results demonstrating objective responses and nearly 10‑month median duration materially de‑rises the BOT+BAL program. Durable efficacy in refractory tumors strengthens the Phase 3 rationale, supports regulatory discussions, and improves partner/license interest over the medium term.
Strengthened Medical LeadershipAdding experienced medical affairs leadership ahead of Phase 3 and early‑access activities improves regulatory engagement, investigator relations and commercialization planning. This enhances the company’s long‑term execution capability to shepherd late‑stage trials, payer dialogue and launch readiness once approvals are secured.
Improved Operational Flexibility From Ligand AmendmentReleasing liens on encumbered assets is a structural improvement that increases strategic optionality: assets can be monetized, used as collateral, or leveraged in partnerships. Over months this can materially ease fundraising or dealmaking constraints and improve operational flexibility.
Bears Say
Negative Equity / Weak Balance SheetNegative stockholders’ equity and elevated leverage are durable governance and financing constraints. They limit access to non‑dilutive capital, raise counterparty and covenant risk, and increase probability of restrictive financing terms or asset sales that can hinder multi‑year clinical development and commercialization plans.
Poor Cash GenerationPersistent negative operating and free cash flows mean the company cannot self‑fund R&D and launches, forcing reliance on external financing or partnerships. Over time this increases dilution risk, can delay programs if funding is constrained, and limits flexibility to scale commercial operations post‑approval.
Material Dilution Risk From Warrant AmendmentLowering the warrant exercise price materially increases the likelihood of exercise and consequent equity issuance. This is a structural capital‑structure change that can dilute existing shareholders, depress per‑share economics from future revenues, and make subsequent fundraising more dilutive over the medium term.
Agenus News
AGEN FAQ
What was Agenus’s price range in the past 12 months?
Agenus lowest stock price was $1.38 and its highest was $7.34 in the past 12 months.
What is Agenus’s market cap?
Agenus’s market cap is $99.30M.
When is Agenus’s upcoming earnings report date?
Agenus’s upcoming earnings report date is Mar 16, 2026 which is in 9 days.
How were Agenus’s earnings last quarter?
Agenus released its earnings results on Nov 10, 2025. The company reported $1.94 earnings per share for the quarter, missing the consensus estimate of $2.197 by -$0.257.
Is Agenus overvalued?
According to Wall Street analysts Agenus’s price is currently Undervalued.
Does Agenus pay dividends?
Agenus does not currently pay dividends.
What is Agenus’s EPS estimate?
Agenus’s EPS estimate is -1.04.
How many shares outstanding does Agenus have?
Agenus has 34,008,350 shares outstanding.
What happened to Agenus’s price movement after its last earnings report?
Agenus reported an EPS of $1.94 in its last earnings report, missing expectations of $2.197. Following the earnings report the stock price went up 5.779%.
Which hedge fund is a major shareholder of Agenus?
Currently, no hedge funds are holding shares in AGEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Agenus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$23.00 (677.03% Upside)
$23.00 (677.03% Upside)
Blogger Sentiment
Neutral
AGEN Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 23.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.3%
Last 30 Days ▲ 6.2%
Last 30 Days ▲ 6.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
25.95%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-1.93%
Trailing 12-Months
Company Description
Agenus
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
AGEN Stock 12 Month Forecast
Average Price Target
$23.00
▲(677.03% Upside)
Technical Analysis
Inovio Pharmaceuticals
―
Oncolytics Biotech
―
―
TuHURA Biosciences
―
Spero Therapeutics
―
Instil Bio
―
Ownership Overview
2.22% Insiders
11.09% Mutual Funds
5.26% Other Institutional Investors
77.16% Public Companies and
Individual Investors